Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial.

Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL

The Journal of clinical endocrinology and metabolism1 Dec 1999Cited by 95 (Europe PMC)

PMID10599727DOI10.1210/jcem.84.12.6241PepBankPUB-10599727

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In girls with Turner syndrome, height SD-score gain was significantly higher with GH group B than group A after 7 yr.
In plain wordsIn girls with Turner syndrome, GH group B increased height SD score more than group A.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight SD-score gain group B versus A
Study
n: not reported in source
Comparator
Group A: 4 IU/m2 day
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day in first year, then 6 IU/m2 day · 7 yearsAs given in this study (human).
Source sentences
Summary
The 7-yr increment in height SD-score was significantly higher in groups B and C than in group A.
4 context sentences(design, population, supporting numbers)
Summary · context
group A, 4 IU/m2 day (approximately 0.045 mg/kg x day); group B, first yr 4, thereafter 6 IU/m2 x day (approximately 0.0675 mg/kg/day);
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972702
02HumanRandomized controlled trialEfficacy outcome
In girls with Turner syndrome, height SD-score gain was significantly higher with GH group C than group A after 7 yr.
In plain wordsIn girls with Turner syndrome, GH group C increased height SD score more than group A.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight SD-score gain group C versus A
Study
n: not reported in source
Comparator
Group A: 4 IU/m2 day
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day first year, 6 second year, then 8 IU/m2 day · 7 yearsAs given in this study (human).
Source sentences
Summary
The 7-yr increment in height SD-score was significantly higher in groups B and C than in group A.
4 context sentences(design, population, supporting numbers)
Summary · context
group C, first yr 4, second yr 6, thereafter 8 IU/m2 x day (approximately 0.090 mg/kg x day).
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972703
03HumanRandomized controlled trialEfficacy outcome
In girls with Turner syndrome who completed GH treatment, the difference between predicted adult height before treatment and achieved height was significantly different between groups C and A (16.0 vs 12.5 cm).
In plain wordsIn girls with Turner syndrome, the gap between predicted and achieved height differed: 16.0 cm in group C, 12.5 cm in group A.
Peptide
HGH (somatotropin)
Outcome
IncreaseDifference between predicted and achieved adult height, group C versus A
Study
n: not reported in source
Comparator
Group A
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day first year, 6 second year, then 8 IU/m2 day · Mean 7.3 years (range 5.0 - 8.75) in the 32 girls who completed the trialAs given in this study (human).
Measurements
Mean difference between predicted adult height and achieved height
16 cm
group C
SD of difference
4.1 cm
group C
Mean difference between predicted adult height and achieved height
12.5 cm
group A
SD of difference
2.1 cm
group A
Source sentences
Summary
The mean (SD) difference between predicted adult height before treatment and achieved height was 12.5 cm (2.1), 14.5 cm (4.0), and 16.0 cm (4.1) for groups A, B, and C, respectively, being significantly different between group A and group C.
3 context sentences(design, population, supporting numbers)
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972710
04HumanNon-randomized trialEfficacy outcome
In girls with Turner syndrome receiving GH, 85% reached a height within the normal range after 7 yr.
In plain wordsIn girls with Turner syndrome receiving GH, 85% reached a normal height range after seven years.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight normalization
Study
n = 68
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Randomized to 4 IU/m2 day (group A); 4 then 6 IU/m2 x day (group B); 4, then 6, then 8 IU/m2 x day (group C) · 7 yearsAs given in this study (human).
Measurements
Girls with height within normal range for healthy Dutch girls
85%
after 7 years of GH, all three dose groups
Source sentences
Summary
After 7 yr, 85% of the girls had reached a height within the normal range for healthy Dutch girls.
3 context sentences(design, population, supporting numbers)
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972701
05HumanNon-randomized trialSafety outcome
In girls with Turner syndrome, GH treatment was well tolerated in all three GH dosage groups.
In plain wordsIn girls with Turner syndrome, GH treatment was well tolerated at all three doses studied.
Peptide
HGH (somatotropin)
Outcome
Not applicableTolerability in all three dose groups
Study
n = 68
Outcome group
Adverse events · Whole body
Studied dose
Randomized to 4 IU/m2 day (group A); 4 then 6 IU/m2 x day (group B); 4, then 6, then 8 IU/m2 x day (group C)As given in this study (human).
Source sentences
Summary
GH treatment was well tolerated in all three GH dosage groups.
3 context sentences(design, population, supporting numbers)
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972711
06HumanNon-randomized trialEfficacy outcome
In girls with Turner syndrome who completed GH treatment, group A mean height was 158.8 cm (SD 7.1).
In plain wordsIn girls with Turner syndrome who completed GH treatment, group A mean height was 158.8 cm.
Peptide
HGH (somatotropin)
Outcome
Not applicableAchieved height group A
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day · Mean 7.3 years (range 5.0 - 8.75) in the 32 girls who completed the trialAs given in this study (human).
Measurements
Mean achieved height
158.8 cm
group A
SD of achieved height
7.1 cm
group A
Source sentences
Summary
Mean (SD) height was 158.8 cm (7.1), 161.0 cm (6.8), and 162.3 cm (6.1) in groups A, B, and C, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated the data of 32 of the 68 girls who had completed the trial after a mean duration of treatment of 7.3 yr (range, 5.0 - 8.75).
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972704
07HumanNon-randomized trialEfficacy outcome
In girls with Turner syndrome who completed GH treatment, group B mean height was 161.0 cm (SD 6.8).
In plain wordsIn girls with Turner syndrome who completed GH treatment, group B mean height was 161.0 cm.
Peptide
HGH (somatotropin)
Outcome
Not applicableAchieved height group B
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day first year, then 6 IU/m2 day · Mean 7.3 years (range 5.0 - 8.75) in the 32 girls who completed the trialAs given in this study (human).
Measurements
Mean achieved height
161 cm
group B
SD of achieved height
6.8 cm
group B
Source sentences
Summary
Mean (SD) height was 158.8 cm (7.1), 161.0 cm (6.8), and 162.3 cm (6.1) in groups A, B, and C, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated the data of 32 of the 68 girls who had completed the trial after a mean duration of treatment of 7.3 yr (range, 5.0 - 8.75).
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972705
08HumanNon-randomized trialEfficacy outcome
In girls with Turner syndrome who completed GH treatment, group C mean height was 162.3 cm (SD 6.1).
In plain wordsIn girls with Turner syndrome who completed GH treatment, group C mean height was 162.3 cm.
Peptide
HGH (somatotropin)
Outcome
Not applicableAchieved height group C
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day first year, 6 second year, then 8 IU/m2 day · Mean 7.3 years (range 5.0 - 8.75) in the 32 girls who completed the trialAs given in this study (human).
Measurements
Mean achieved height
162.3 cm
group C
SD of achieved height
6.1 cm
group C
Source sentences
Summary
Mean (SD) height was 158.8 cm (7.1), 161.0 cm (6.8), and 162.3 cm (6.1) in groups A, B, and C, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated the data of 32 of the 68 girls who had completed the trial after a mean duration of treatment of 7.3 yr (range, 5.0 - 8.75).
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972706
09HumanNon-randomized trialEfficacy outcome
In girls with Turner syndrome who completed GH treatment, the difference between predicted adult height before treatment and achieved height was 12.5 cm (SD 2.1) in group A.
In plain wordsIn girls with Turner syndrome who completed GH treatment, achieved height differed from the height predicted before treatment by 12.5 cm in group A.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedDifference between predicted and achieved adult height, group A
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day · Mean 7.3 years (range 5.0 - 8.75) in the 32 girls who completed the trialAs given in this study (human).
Measurements
Mean difference between predicted adult height and achieved height
12.5 cm
group A
SD of difference
2.1 cm
group A
Source sentences
Summary
The mean (SD) difference between predicted adult height before treatment and achieved height was 12.5 cm (2.1), 14.5 cm (4.0), and 16.0 cm (4.1) for groups A, B, and C, respectively, being significantly different between group A and group C.
4 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated the data of 32 of the 68 girls who had completed the trial after a mean duration of treatment of 7.3 yr (range, 5.0 - 8.75).
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972707
10HumanNon-randomized trialEfficacy outcome
In girls with Turner syndrome who completed GH treatment, the difference between predicted adult height before treatment and achieved height was 14.5 cm (SD 4.0) in group B.
In plain wordsIn girls with Turner syndrome who completed GH treatment, achieved height differed from the height predicted before treatment by 14.5 cm in group B.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedDifference between predicted and achieved adult height, group B
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day first year, then 6 IU/m2 day · Mean 7.3 years (range 5.0 - 8.75) in the 32 girls who completed the trialAs given in this study (human).
Measurements
Mean difference between predicted adult height and achieved height
14.5 cm
group B
SD of difference
4 cm
group B
Source sentences
Summary
The mean (SD) difference between predicted adult height before treatment and achieved height was 12.5 cm (2.1), 14.5 cm (4.0), and 16.0 cm (4.1) for groups A, B, and C, respectively, being significantly different between group A and group C.
4 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated the data of 32 of the 68 girls who had completed the trial after a mean duration of treatment of 7.3 yr (range, 5.0 - 8.75).
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972708
11HumanNon-randomized trialEfficacy outcome
In girls with Turner syndrome who completed GH treatment, the difference between predicted adult height before treatment and achieved height was 16.0 cm (SD 4.1) in group C.
In plain wordsIn girls with Turner syndrome who completed GH treatment, achieved height differed from the height predicted before treatment by 16.0 cm in group C.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedDifference between predicted and achieved adult height, group C
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
4 IU/m2 day first year, 6 second year, then 8 IU/m2 day · Mean 7.3 years (range 5.0 - 8.75) in the 32 girls who completed the trialAs given in this study (human).
Measurements
Mean difference between predicted adult height and achieved height
16 cm
group C
SD of difference
4.1 cm
group C
Source sentences
Summary
The mean (SD) difference between predicted adult height before treatment and achieved height was 12.5 cm (2.1), 14.5 cm (4.0), and 16.0 cm (4.1) for groups A, B, and C, respectively, being significantly different between group A and group C.
4 context sentences(design, population, supporting numbers)
Summary · context
In addition, we evaluated the data of 32 of the 68 girls who had completed the trial after a mean duration of treatment of 7.3 yr (range, 5.0 - 8.75).
Summary · context
To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2-11 yr, who were randomly assigned to one of three GH dosage groups:
Summary · context
In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls.
Summary · context
Thereafter, girls started with 17beta-estradiol (5 microg/kg bw x day, orally) when they had reached the age of 12 yr.
Report a problemFND-1059972709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01518062

Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

Novo Nordisk A/Sn = 65Nov 1989 to Sept 2003

Genetic Disorder · Turner Syndrome

Trial page ClinicalTrials.govUpdated 18 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.